Swedish Orphan returns Mimpara rights to Amgen

Swedish Orphan Biovitrum AB (SSE:SOBI) will return co-promotion rights in Nordic countries to Amgen Inc. (NASDAQ:AMGN) for hyperparathyroidism and hypercalcemia drug Mimpara cinacalcet. Swedish Orphan will receive an undisclosed payment for the return of rights. The company had SEK26.2 million ($3.9 million) in 2009 co-promotion revenue for the second-generation calcimimetic. Amgen, which has rights to cinacalcet from NPS Pharmaceuticals Inc. (NASDAQ:NPSP), markets it in the U.S. as Sensipar. ...